Neuroprotective Effect of (Nano PSO), in Patients Who Used to Consume Psychoactive Substances

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Addiction;Drug(S);LSD, Neuroprotective

In brief

Addiction problems to psychoactive substances are becoming more frequent, which implies a serious health problem, with social, family and work repercussions. Participants with chronic consumption present important degeneration processes mediated by Neuroinflammation, oxidative stress and excitotoxicity. At the moment there is no effective treatment that can reduce the damage. The effectiveness of Omega 5 has been demonstrated in different disorders of the nervous system; However, very little has been elucidated about the mechanisms of regulation and activation in consumer patients. Omega 5 Nano-PSO has an important role in mechanisms of cell survival in different pathological events. In this project aims to explain the possible mechanisms underlying the morphological changes and pathologies associated with oxidative stress and inflammation, since it could be a useful strategy to counteract the effects of substances of abuse on brain cells. Omega 5 (Nano PSO) will modify the levels of neurotrophic factors through the decrease in inflammation and reactive oxygen species in patient-consumers of substances, reducing neuronal death and therefore cognitive deterioration. Methodological design Type of study: Clinical trial, randomized controlled, double blind. Research Headquarters: This work will be carried out at the University Center for Health Science with the participation of the "My family is waiting for me" rehabilitation centers. Study Period: 2 years

Key facts

Study ID

NCT06550167

Run by

Distribuidora Biolife SA de CV

People needed

80

Starts

2024-03-15

Expected to finish

2027-03-15

Last updated by the study team

2024-08-12

Who can join

Age: 18 and older, up to 50. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patients who are multiple users of methamphetamines, cocaine, and cannabis with or without alcohol and tobacco, and have a history of at least 3 years of consumption.
• Patients who accept informed consent to participate in the protocol.
• Male gender.
• Age between 18-50 years in the withdrawal phase currently in residential treatment

You may not qualify if…

• Individuals under 18 years of age.
• Patients who do not sign the informed consent.
• Discharge of patients prior to the stipulated 6 months, requested by family members.
• Patients with developed or known allergies.
• Patients who are consuming NSAIDs, MAOIs (monoamine oxidase Inhibitor), active chronic inflammatory diseases, or any type of cancer

Where it is running

• Irene Guadalupe Aguilar García PhD. — Guadalajara, Jalisco, Mexico (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.